UCB’s 2024 Performance: A Year of Innovation and Impact

December 31, 2024 — As we reflect on the past year, UCB’s 2024 financial and extra-financial performance underscores the relevance of its guiding principle: “Inspired by patients, driven by science.” The pharmaceutical company has made significant strides in breakthrough innovation and execution excellence, delivering transformative value to people living with severe diseases.

Twelve months ago, UCB set ambitious goals to launch new solutions that make a real difference. Today, those efforts have come to life. The company has delivered on its commitments, and the results speak for themselves. “We deliver on our commitments, and the results speak for themselves,” said the company in its annual report.

UCB’s 2024 revenue increased by 17% to €6.15 billion, driven by net sales of €5.61 billion. This growth was fueled by the triple and double-digit performance of its growth medicine drivers. Underlying profitability rose by 9% to €1.48 billion, and profit more than tripled. Looking ahead, UCB aims to achieve revenues in 2025 in the range of €6.5 to €6.7 billion and an adjusted EBITDA to reach 30% of revenues, representing a significant increase over 2024 considering the evolution of its medicine portfolio.

Since 2014, UCB’s revenue has increased by around 80%, adjusted EBITDA by more than 130%, and its market capitalization has tripled. This growth trajectory is a testament to the company’s strategic initiatives and innovative approach to healthcare solutions.

UCB’s 2024 results go beyond financial performance. Sustainability continues to be central to everything the company does. Scientific progress must be responsible, and growth should not come at the expense of the environment. UCB is proud that its net-zero climate targets have been validated by the Science-Based Targets initiative, holding the company accountable for reducing its carbon footprint. The company’s ESG performance, assessed by organizations such as Sustainalytics, ISS ESG, MSCI, and CDP, has placed it among industry leaders, reaffirming its responsibility to future generations.

Beyond reducing emissions, UCB is committed to equitable healthcare access. This year, the company expanded its reach by 3% to reach 82% access coverage for its medicines, ensuring that more people—regardless of location or socioeconomic status—can access life-changing treatments. This initiative is particularly relevant in the U.S., where healthcare access remains a pressing issue. For example, the expansion of telemedicine during the COVID-19 pandemic has highlighted the need for equitable access to healthcare services, and UCB’s efforts align with this broader trend.

UCB’s commitment to innovation and sustainability is evident in its recent developments. The company has been at the forefront of developing treatments for rare diseases, such as epilepsy and immune disorders. For instance, UCB’s drug Epidiolex, approved by the FDA for the treatment of seizures associated with rare forms of epilepsy, has been a game-changer for patients. This drug exemplifies UCB’s dedication to “breakthrough innovation” and its mission to deliver transformative value to patients.

With a strong foundation in innovation, ongoing launches of key medicines, financial stability, and positive societal impact, UCB is confident about the road ahead. 2025 will bring continued momentum, driven by strong execution, sustained growth, and breakthrough innovation that delivers meaningful impact.

To UCB’s team members, partners, and stakeholders, the company extends its gratitude. “To my team members, partners, and stakeholders – thank you for being part of this journey. Your dedication makes this possible. Together, we will continue to transform the lives of people living with severe diseases and shape the future of healthcare in a responsible and impactful way,” the company stated.

As UCB looks to the future, it remains committed to its guiding principles and continues to push the boundaries of scientific innovation. The company’s achievements in 2024 serve as a blueprint for what is possible when science and sustainability are at the forefront of corporate strategy. With a focus on delivering transformative value to patients and ensuring equitable healthcare access, UCB is poised to make an even greater impact in the years to come.

For those interested in following UCB’s journey, the company’s annual report and sustainability initiatives provide a comprehensive overview of its achievements and future goals. The report highlights the company’s commitment to innovation, sustainability, and equitable healthcare access, offering a roadmap for other organizations looking to make a positive impact on society.

In conclusion, UCB’s 2024 performance is a testament to the power of innovation and sustainability in driving meaningful impact. As the company continues to push the boundaries of scientific progress, it remains dedicated to its mission of transforming the lives of people living with severe diseases and shaping the future of healthcare in a responsible and impactful way.